Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sucampo Pharma Inc (SCMP) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 524,830
  • Shares Outstanding, K 45,830
  • Annual Sales, $ 153,180 K
  • Annual Income, $ 33,370 K
  • 36-Month Beta 1.71
  • Price/Sales 2.47
  • Price/Book 3.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.95 +2.28%
on 01/23/17
14.20 -21.13%
on 01/04/17
-2.10 (-15.79%)
since 12/23/16
3-Month
10.60 +5.66%
on 11/02/16
17.55 -36.18%
on 11/30/16
-1.26 (-10.11%)
since 10/21/16
52-Week
9.59 +16.79%
on 03/17/16
17.55 -36.18%
on 11/30/16
-2.46 (-18.01%)
since 01/22/16

Most Recent Stories

More News
Gilead (GILD) HCV Therapy Application Validated in Europe

Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated....

Bristol-Myers Settles Litigation with Merck for Keytruda

Bristol-Myers Squibb Company (BMY) along with partner Ono Pharmaceutical Company, Ltd. announced that both the companies have signed a global patent license agreement with Merck & Co., Inc. (MRK) to settle...

Prima Biomed Initiates Randomized Study for Breast Cancer

Prima (PBMD) dosed the first patient in the enlarged randomized phase of the phase IIb study -- AIPAC -- on IMP321 for the treatment of metastatic breast cancer.

Synergy (SGYP) Trulance Wins FDA Approval for Constipation

Synergy Pharmaceuticals Inc. (SGYP) announced that the FDA has approved one of its lead pipeline candidates, Trulance (plecanatide), for the treatment of adults suffering from chronic idiopathic constipation...

Allergan (AGN) Rhofade Cream for Rosacea Approved in U.S.

Allergan plc (AGN) announced that the FDA has approved Rhofade (oxymetazoline hydrochloride) cream for topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

Drug Makers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Sucampo Pharma, and Pernix Therapeutics

Stock-Callers.com today evaluates the following Drug Manufacturers equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP), and...

Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study

Bioblast (ORPN) announced results from a phase IIa study on trehalose for the treatment of patients with spinocerebellar ataxia type 3.

Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.

Benitec Stock Up on Orphan Drug Status for BB-301 in EU

Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones...

See More

Support & Resistance

2nd Resistance Point 11.83
1st Resistance Point 11.52
Last Price 11.20
1st Support Level 10.92
2nd Support Level 10.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.